Articles related to MEDICAL DIAGNOSTICS

Researchers used retinal imaging to examine the eyes of 200 people with age-related macular degeneration (AMD) to see who had subretinal drusenoid deposits (SDDs). Patients were asked to fill out a questionnaire about their family history of cardiovascular disease. There were 97 SDDs and 103 drusen only among the 200 patients. 47 of the 200 patients had severe heart disease, and 40 of the 47 (86%) had SDDs. In comparison, 57 (43%) of the 153 AMD patients who did not have these severe diseases had SDDs. According to the researchers, AMD patients who had these severe cardiovascular diseases and strokes were nine times more likely to have SDDs than those who did not.

This trial included 33 patients with clinical node-positive locally advanced breast cancer who underwent NET and breast surgery. MRI exams were performed before the first treatment regimen, at least two months after the first treatment cycle but prior to crossing-over, and immediately before surgery. MRI did not demonstrate sufficient diagnostic performance to avoid surgical axillary staging in the authors’ analysis.

In this 3rd case in a short series, the author describes integration of next-generation PSMA imaging with conventional imaging, including CT and bone scans. The author reviews the rationale for triple therapy with darolutamide, ADT, and docetaxel, and reviews the key phase III studies on triple therapy in prostate cancer: the ENZAMET, PEACE-1 and ARASENS trials.

Dr. Janos Tanyi, Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania, is joined by Dr. Charles Turck to discuss fluorescence-guided, intraoperative imaging as well as a new imaging drug to help physicians better detect ovarian cancer.

This “1-Minute Consult” discusses what constitutes bile duct dilation, clinical evaluation, imaging options for workups, clinical approach to the evaluation, and take-home points, along with figures, tables, info, and metrics on the condition.

Results of a MEDLINE review highlight numerous studies across different cancer types indicating that ctDNA-based MRD detection predicts recurrence with high sensitivity and specificity, and with lead times that precede standard imaging by up to 12 months.